Renu Eapen

Prostate‐specific membrane antigen positron emission tomography/computed tomography funding grants free access to superior staging for Australian men with prostate cancer

N. Lawrentschuk, D. Murphy, M. Hofman, 2022 .

NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial

N. Lawrentschuk, D. Murphy, S. Siva, 2023, Contemporary clinical trials communications.

Role of FDG PET/CT in Management of Patients with Prostate Cancer.

D. Murphy, M. Hofman, A. Azad, 2023, Seminars in nuclear medicine.

Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma

N. Lawrentschuk, D. Murphy, B. Tran, 2022, European urology open science.

PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics

M. Cooperberg, N. Lawrentschuk, D. Murphy, 2018, World Journal of Urology.

Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study.

N. Lawrentschuk, P. Jackson, S. Sandhu, 2023, European urology.